Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling
- PMID: 34530004
- DOI: 10.1016/j.xphs.2021.09.013
Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling
Abstract
Azithromycin is an antibiotic listed in the essential list of medicines for adults and pediatrics. Conflicting evidence has been found regarding azithromycin classification according to the Biopharmaceutics classification system (BCS). The purpose of this study was to identify the critical variables that influence the oral absorption of azithromycin in adults and pediatrics. Azithromycin solubility and dissolution studies (oral suspension) were performed in buffers and biorelevant media simulating the fasted and fed gastrointestinal tract. A PBPK model was developed for azithromycin for healthy adult volunteers and pediatrics (Simcyp® v18.2) informed by in vitro solubility and dissolution studies to predict drug performance after administration of azithromycin as an oral suspension. The developed PBPK model predicted azithromycin plasma concentrations-time profiles after administration of an oral suspension to adults and pediatrics. Sensitivity analysis of solubility vs dose suggests that absorption is independent of solubility within the therapeutic dose range in both adults and pediatrics. The developed PBPK model for adults and pediatrics was consistent with the mechanism of permeation through the intestinal membrane (passive and active processes) being the rate-limiting step of azithromycin's absorption. The physiologically based approach proposed was shown to be useful to determine the factors controlling drug absorption in adults and pediatrics.
Keywords: Absorption; Biopharmaceutics classification system (BCS); Pediatric; Permeability; Physiologically Based Pharmacokinetic (PBPK) modeling; Solubility.
Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.AAPS J. 2022 Jan 10;24(1):27. doi: 10.1208/s12248-021-00662-1. AAPS J. 2022. PMID: 35013803 Free PMC article.
-
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.Mol Pharm. 2017 Dec 4;14(12):4305-4320. doi: 10.1021/acs.molpharmaceut.7b00406. Epub 2017 Aug 25. Mol Pharm. 2017. PMID: 28771009
-
In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.Mol Pharm. 2017 Dec 4;14(12):4321-4333. doi: 10.1021/acs.molpharmaceut.7b00396. Epub 2017 Sep 5. Mol Pharm. 2017. PMID: 28817288
-
Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):833-42. doi: 10.1016/j.ejpb.2013.04.015. Epub 2013 May 9. Eur J Pharm Biopharm. 2013. PMID: 23665448 Review.
-
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.Eur J Pharm Biopharm. 2020 Oct;155:55-68. doi: 10.1016/j.ejpb.2020.08.005. Epub 2020 Aug 8. Eur J Pharm Biopharm. 2020. PMID: 32781025 Review.
Cited by
-
Azithromycin-Loaded Nanoparticles Incorporated in Chitosan-Based Soft Hydrogels: A Novel Approach for Dental Drug Delivery.Pharmaceutics. 2025 Feb 26;17(3):304. doi: 10.3390/pharmaceutics17030304. Pharmaceutics. 2025. PMID: 40142968 Free PMC article.
-
Formulation of Thermo-Sensitive In Situ Gels Loaded with Dual Spectrum Antibiotics of Azithromycin and Ofloxacin.Polymers (Basel). 2024 Oct 22;16(21):2954. doi: 10.3390/polym16212954. Polymers (Basel). 2024. PMID: 39518163 Free PMC article.
-
Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.AAPS J. 2024 Apr 4;26(3):44. doi: 10.1208/s12248-024-00912-y. AAPS J. 2024. PMID: 38575716
-
Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment.Front Pharmacol. 2022 Aug 16;13:838599. doi: 10.3389/fphar.2022.838599. eCollection 2022. Front Pharmacol. 2022. PMID: 36052120 Free PMC article.
-
Pharmacokinetics and Histotoxic Profile of a Novel Azithromycin-Loaded Lipid-Based Nanoformulation.AAPS PharmSciTech. 2024 Jul 9;25(6):157. doi: 10.1208/s12249-024-02861-3. AAPS PharmSciTech. 2024. PMID: 38982006
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources